La vendita allo scoperto per Brookfield Renewable dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Brookfield Renewable. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Brookfield Renewable (NYSE:BEPC) Azioni, Report sulle vendite allo scoperto

Brookfield Renewable

Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia, and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners LP and Brookfield Renewable Corp.

Ordinary Shares - Class A (Exchangeable Sub Voting)

Brookfield Renewable Corporation Brookfield Renewable Corporation Class A Subordinate Voting Shares

Brookfield Renewable Corp

Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) reported better-than-expected earnings for the first quarter, but <a href="https://www.benzinga.com/quote/G/earnings">lowered its FY25 earnings outlook.</a>
The company posted quarterly earnings of 84 cents per share which beat the analyst consensus estimate of 79 cents per share. The company reported quarterly sales of $1.21 billion which met the analyst consensus estimate.
&#8220;We entered 2025 with strong momentum. Revenue in the first quarter grew 8% year-over-year with Data-Tech-AI revenue up 12%, on a constant currency basis, driving adjusted EPS growth of 16%. Looking ahead, our deep process and domain expertise remains a key competitive advantage as we partner with clients to optimize costs and accelerate transformation using AI and other advanced technologies,&#8221; said Balkrishan &#8220;BK&#8221; Kalra, Genpact&#8217;s President &amp; CEO. &#8220;Although the operating environment has changed since the beginning of the year, the strength of our business model and resilience of our strategy remain clear. We believe our continued focus on accelerating innovation, deepening client relationships, and driving results positions us to accelerate growth in the future.&#8221;
Genpact lowered its FY2025 GAAP EPS guidance from $3.04-$3.11 to $2.90-$3.01. The company also slashed its FY2025 adjusted EPS guidance from $3.52-$3.59 to $3.41-$3.52.
Genpact shares fell 0.3% to close at $49.55 on Wednesday.
These analysts made changes to their price targets on Genpact following earnings announcement.
<ul>
<li>Needham analyst Mayank Tandon maintained Genpact with a Buy and lowered the price target from $55 to $50.</li>
<li>Baird analyst David Koning maintained the stock with a Neutral and lowered the price target from $56 to $50.</li>
</ul>
Considering buying G stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08092459/image-85-1024x583.png" alt="" class="wp-image-908000" style="width:560px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08092459/image-85-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08092459/image-85-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08092459/image-85-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/08092459/image-85.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45251088/top-3-financial-stocks-that-may-plunge-in-may">Top 3 Financial Stocks That May Plunge In May</a> </li>
</ul>
Photo via Shutterstock

Earnings

News

Price Target

Markets

Analyst Ratings

Trading Ideas

Genpact Analysts Cut Their Forecasts After Q1 Results

Experienced partner to launch rollout of up to hundreds of GPS monitoring units from SuperCom's PureSecurity Suite
TEL AVIV, Israel, May 8, 2025 /PRNewswire/ -- SuperCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>),&nbsp;a global provider of secured solutions for the e-Government, IoT, and cybersecurity sectors, today announced that it has signed a new contract with a seasoned electronic monitoring service provider based in Canada. This agreement marks another milestone in SuperCom's North American expansion and reinforces its growing global presence in the electronic monitoring (EM) market.

SPCB

SuperCom Signs New Contract With Electronic Monitoring Service Provider Based In Canada

United States Antimony (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAMY#AMEX">UAMY</a>) reported $7.00 million in sales this quarter. This is a 147.26 percent increase over sales of $2.83 million the same period last year.

UAMY

United States Antimony Q1 Sales $7.00M Up From $2.83M YoY

Baird analyst Jeffrey Meuler maintains Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) with a Outperform and raises the price target from $320 to $335.

VRSK

Baird Maintains Outperform on Verisk Analytics, Raises Price Target to $335

<a href="https://www.globenewswire.com/Tracker?data=Stnp4f2xkXdpdYz1XNTV4fG-mxc9cEb67No2uRpooNh77GiFKyX2y60dQdr3a9jkkyIMy7bDRsxTwMCGhxS3sA==">Beam Global</a>, (Nasdaq:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=y7LjIf-CxUruvr0IxihRYXPESjxXfpb8ywora3Cep3nWv8Clrr9wKrA4fm9JOkmdukwgO-3TdYgV2zaMvW8FYkSsL46rj-76yuKs3xGAaMQ=">BEEM</a>), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation and energy security, today announced a broad range of new orders for its <a href="https://www.globenewswire.com/Tracker?data=GB9E4tY8IOq_Pe44uZ7AmSktSlndoUSRFoQKwipvMlplLN-blYPEYxZRs214fpZgdsPYy69bGg6Y3rDo_Dt41cn0wRIf6Tsyn_9jQMNcUgU=">EV ARC&#x2122;</a> off-grid solar-powered charging units, despite a reduction in federal demand. The 23% quarter-over-quarter increase in orders reflects growing demand for clean, resilient infrastructure solutions across a wide variety of sectors and regions.
Recent orders were placed by a mix of municipal and county governments, state and federal agencies, environmental organizations, and private sector companies including those in construction, clean energy, and technology. The orders came from multiple states including California, Arizona, Colorado, Florida, Michigan, and Washington.

Contracts

BEEM

Beam Global Reports 23% QoQ Surge In Orders For EV ARC Off-Grid Solar Charging Units

WIIM

WRBY

WRBY stock has given up its prior loss. Warby Parker shares were trading lower after the company missed Q1 estimates and lowered its FY25 sales guidance.

Baird analyst David Koning maintains Verra Mobility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRRM#NASDAQ">VRRM</a>) with a Outperform and raises the price target from $27 to $28.

VRRM

Baird Maintains Outperform on Verra Mobility, Raises Price Target to $28

Use of AI and machine learning accelerates identification of patient groups whose care can be improved
First study examines pro-inflammatory TNF-α levels in patients receiving GLP-1 agonists including Wegovy&#xAE; or Ozempic&#xAE;
Initial findings support opportunities to improve diagnosis and treatment and demonstrate isomyosamine's potential to impact quality of life in a general practice population
TNF Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health, a company committed to focusing on outpatient care to minimize costs, impact and the need for hospitalization, today announced positive results from the first stage of a general practice population study focusing on patients receiving GLP-1 agonists. The study series is expected to evaluate the impact of the Company's novel oral TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in preserving lean muscle mass during and after GLP-1 treatment for weight loss and chronic weight management in patients who are a) on GLP-1 agonists, b) candidates for treatment with GLP-1 agonists, or c) probably not suitable for treatment with weight loss therapy.
In coordination with Renova Health, the purpose of this first stage was to analyze 30,000 patients already under the care of primary care physicians and identify convergences between the use of GLP-1 agonists and chronic disorders linked with increased risk of inflammation. The data were parsed into three cohorts depending on prespecified criteria. TNF plans to use these data to optimize appropriate patient recruitment and accelerate isomyosamine drug development.

Biotech

General

TNFA

TNF Pharmaceuticals And Renova Health Announce Initial Results From AI-Driven Study Of 30K Patients On GLP-1 Agonists, Highlighting Potential Of Isomyosamine To Improve Diagnosis, Preserve Muscle Mass, And Enhance Treatment For Inflammatory Conditions

VTRS

Viatris shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 adjusted EPS guidance.

Wells Fargo analyst Cerena Chen maintains Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) with a Overweight and lowers the price target from $40 to $35.

AMPH

Wells Fargo Maintains Overweight on Amphastar Pharma, Lowers Price Target to $35

Baird analyst Jon Vruwink maintains Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) with a Neutral and raises the price target from $84 to $90.

QTWO

Baird Maintains Neutral on Q2 Holdings, Raises Price Target to $90

ABEV

Ambev shares are trading higher following Q1 financial results.

<a href="https://www.globenewswire.com/Tracker?data=u3BgzIQ7W6gaaNsksAWiO5_3u-zGn7J115dtO8yObSQEK9bGZmyaw8whtfwqqSWJvLvOCmDKwvV5GFDJ068VW7XpxC8bJsBjdYwdOBKIVe0GVioTN9GdkfTPsBKaKxGc">SS Innovations International, Inc.</a> (the "Company" or "SS Innovations") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company is planning to submit a De Novo Classification Request to the U.S. Food and Drug Administration (the "FDA") for the SSi Mantra 3 surgical robotic system (the "SSi Mantra 3") in July 2025.&nbsp; &nbsp;
If approved by the FDA, the SSi Mantra 3 would be cleared to market in the United States. Submission of the De Novo Classification Request does not guarantee FDA approval.
Since the Company began the sale of its system in August 2022 it has installed a total of 80 SSi Mantra robotic surgical systems in 75 hospitals and over 3,800 surgeries have been performed, including over 200 robotic cardiac surgeries. The SSi Mantra 3 version was launched in June 2024, and the Company has already installed 37 systems that have been utilized to perform more than 750 multispecialty robotic surgical procedures, including 70 cardiac cases, with no device related mortality, injury or complications.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Real world clinical data, validated by a leading contract research organization ("CRO"), supports the ability of the SSi Mantra 3 to safely perform a wide variety of surgical procedures. The planned submission of the SSi Mantra 3 to the FDA will include an application for multispecialty indications including urology, gynecology, general surgery, and thoracic and cardiac surgery.

SSII

SS Innovations To Submit De Novo Request To FDA In July 2025 For SSi Mantra 3 Surgical Robotic System

Bank of America is doubling down on its call that the Federal Reserve will not cut interest rates in 2025, underscoring the central bank's growing discomfort with a dual threat of rising inflation and unemployment revealed at <a href="https://www.benzinga.com/topic/federal-reserve">this week's policy meeting.</a>
In a note shared Thursday, BofA economist Aditya Bhave said the key takeaway from the May Federal Open Market Committee meeting was "an upgrade to the Fed&#8217;s assessment of economic uncertainty." 
Bhave referred to two new lines in the Fed's statement: first, that uncertainty "has increased further," and second, "risks of higher unemployment and higher inflation have risen."
<h3 class="wp-block-heading">Hawkish Tilt As Fed Acknowledges Stagflation Risks</h3>
While the Fed kept rates unchanged at 4.25%-4.50%, Chair Jerome Powell's press conference took a cautious, hawkish tone compared to March.
Powell repeatedly emphasized the central bank's comfort with staying on hold and made clear that the Fed would not act preemptively—unlike in 2019 when it delivered three rate cuts as inflation was running well below target.
That's not the case today. Core inflation has exceeded the Fed's 2% target for four straight years, giving policymakers far less room to maneuver. 
Bhave said Powell's message was clear: "Uncertainty is high, and the Fed is comfortable staying on hold until there is greater clarity."
<h3 class="wp-block-heading">Higher Bar For Cuts, Markets Start To Adjust</h3>
According to Bhave, this approach means the hurdle for a June cut is now significantly higher. 
Market expectations have already begun to reflect that shift. 
The CME FedWatch tool shows that the probability of a June rate cut tumbled to 16% on Thursday &#8211; down from 28% before Powell's remarks. The chances of a July move are 65%, down from 92% a week ago.
BofA's base case assumes a steady labor market paired with renewed inflationary pressures—conditions that effectively rule out any Fed rate cuts.
"If our base case of a steady labor market and rising inflation is correct, we don&#8217;t see a path to cuts in 2025," Bhave said.
<h3 class="wp-block-heading">Implications For Markets</h3>
BofA rate strategist Mark Cabana said front-end Treasury yields could move higher as investors increasingly price out near-term rate cuts. He also recommends staying underweight in longer-dated Treasuries, where issuance—particularly in the 30-year tenor—continues to exceed demand.
BofA maintains a broadly bearish stance on the U.S. dollar despite adopting a more hawkish-than-consensus view on the rate outlook. Cabana said the dollar remains "notably dislocated from short-term rate differentials," and that this misalignment is unlikely to correct through subtle shifts in Fed language alone.
"We remain broadly dollar-bearish, and negative sentiment more broadly has increased over the past month, with many re-thinking broader allocations to U.S. assets and/or FX hedges," the investment bank said.
The U.S. dollar index – as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – has fallen 8% year-to-date, on track for its worst year since 2017. 
 Read now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45269703/stagflation-emerges-as-key-economic-risk-to-federal-reserve-policy-economists-warn">Stagflation Emerges As Key Risk To Fed Policy, Economists Warn: &#8216;We&#8217;re Grappling With A Rare Trifecta&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Macro Economic Events

Bonds

Currency ETFs

Forex

Treasuries

Econ #s

Economics

ETFs

PowerShares DB US Dollar Index Bullish Fund

Forget Rate Cuts This Year, Bank Of America Warns After Powell's Hawkish Tone

CART

Maplebear shares are trading lower after the company announced the resignation of its CEO.

Baird analyst Rob Oliver maintains ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) with a Neutral and lowers the price target from $7 to $5.

ONTF

Baird Maintains Neutral on ON24, Lowers Price Target to $5

Banco Bradesco shares are trading higher following a year-over-year increase in Q1 sales results.

Baird analyst David Koning maintains Genpact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) with a Neutral and lowers the price target from $56 to $50.

Baird Maintains Neutral on Genpact, Lowers Price Target to $50

CCOI

Cogent Communications shares are trading lower after the company reported worse-than-expected Q1 financial results.

Wells Fargo analyst Stan Berenshteyn maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Equal-Weight and lowers the price target from $10 to $8.

Comments

Brookfield Renewable

Vendite allo scoperto

Brookfield Renewable (NYSE:BEPC) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO